Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 10, Pages e003050
Publisher
BMJ
Online
2021-10-19
DOI
10.1136/jitc-2021-003050
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
- (2021) François Anna et al. Journal for ImmunoTherapy of Cancer
- Engineering Chimeric Antigen Receptor T cells Against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
- (2020) Ching-Yao Yang et al. Molecular Therapy-Oncolytics
- Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
- (2020) Soo-Chin Lee et al. CLINICAL CANCER RESEARCH
- Targeting PD-L1 in non-small cell lung cancer using CAR T cells
- (2020) Ming Liu et al. Oncogenesis
- CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
- (2020) Alba Rodriguez-Garcia et al. Frontiers in Immunology
- HLA-G Neo-Expression on Tumors
- (2020) Maria Loustau et al. Frontiers in Immunology
- Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
- (2020) Le Qin et al. Biomarker Research
- Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial
- (2020) Gabriele Multhoff et al. CLINICAL CANCER RESEARCH
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- HLA-G Expressing Immune Cells in Immune Mediated Diseases
- (2020) P. Contini et al. Frontiers in Immunology
- CAR-NK cells: A promising cellular immunotherapy for cancer
- (2020) Guozhu Xie et al. EBioMedicine
- Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
- (2020) Ahmet Yilmaz et al. Journal of Hematology & Oncology
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
- (2019) Hongwei Du et al. CANCER CELL
- Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series
- (2019) Swetha Kambhampati et al. Clinical Lymphoma Myeloma & Leukemia
- Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
- (2018) Junjie Wu et al. CANCER LETTERS
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- CART Targeting of Solid Tumors: More Pieces to the Puzzle
- (2018) Michael Kalos CLINICAL CANCER RESEARCH
- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-β and Engagement of CD85j
- (2017) Sol Y. Nuñez et al. JOURNAL OF IMMUNOLOGY
- Can we predict protein from mRNA levels?
- (2017) Nikolaus Fortelny et al. NATURE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
- (2017) Cornelia Siebenkäs et al. PLoS One
- The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
- (2017) John P. Veluchamy et al. Frontiers in Immunology
- Prospects for combined use of oncolytic viruses and CAR T-cells
- (2017) Adam Ajina et al. Journal for ImmunoTherapy of Cancer
- The untold story of IFN-γ in cancer biology
- (2016) M. Alper Kursunel et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Natural Killer Cell Adoptive Transfer Therapy
- (2015) Zachary B. Davis et al. CANCER JOURNAL
- B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity
- (2015) M-R Wu et al. GENE THERAPY
- Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome
- (2015) Cláudia C. Oliveira et al. Frontiers in Immunology
- Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes
- (2015) Veronika Vlková et al. Oncotarget
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Pathways: Human Leukocyte Antigen G (HLA-G)
- (2013) G. Curigliano et al. CLINICAL CANCER RESEARCH
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor
- (2012) Mirna Balsamo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- NK cytolysis is dependent on the proportion of HLA-G expression
- (2012) Bao-Guo Chen et al. HUMAN IMMUNOLOGY
- Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor
- (2012) STEVEN G. GRAY et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
- (2012) Zhili Zheng et al. Journal of Translational Medicine
- Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
- (2012) Steven J Potts et al. LABORATORY INVESTIGATION
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Beyond the increasing complexity of the immunomodulatory HLA-G molecule
- (2008) E. D. Carosella et al. BLOOD
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
- (2008) Carlo Stresemann et al. INTERNATIONAL JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search